絞り込み

16555

広告

Helicobacter pylori therapy and clinical perspective.

著者 Talebi Bezmin Abadi A , Yamaoka Y
J Glob Antimicrob Resist.2018 Mar 23 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (156view , 0users)

Full Text Sources

Helicobacter pylori (H. pylori) infection induces chronic gastritis and duodenal ulcer in small fraction of infected population. Three decades after introduction of the H. pylori and disclosure of urgent need for eliminating the bacterium in patients, it seems that we are still in first steps of dealing with this mysterious organism. H. pylori treatment is a complex dilemma for clinicians, a repeating sentence by many of scientists whom spend years on this research topic. Apart from many modifications in initial first-line treatment of H. pylori, gastroenterologists are unable to overcome the problem of therapeutic failures. Choosing the best regimens in any regions depends on many factors which are in focus of many randomized clinical trials. A potential increase in efficacy of future therapies may be influenced by adding the novel potassium-competitive acid blocker as termed Vonoprazan. Undeniably, in-depth analysis is necessary to suggest more effective therapeutic regimens. Meanwhile, we recommend the performance of susceptibility tests before any antibiotic proscription.
PMID: 29581076 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード